Biogen
BIIB
Performance
About Biogen
Biogen is a global biotechnology company focused on discovering, developing, and delivering innovative medicines for serious neurological and rare diseases such as multiple sclerosis, Alzheimer's disease, ALS, spinal muscular atrophy, and lupus. Leveraging deep expertise in human biology and multiple therapeutic modalities, Biogen advances first‑in‑class treatments through extensive R&D, clinical trials, and early‑access programs, while emphasizing health equity, sustainability, and patient advocacy across its worldwide operations.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Whoop Secures $575 M Series G, Hits $10 B Valuation Ahead of IPO
PharmaShots Magazine-April-2026 Edition
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
What’s the Deal with Alzheimer’s Disease and Amyloid?
Here Are Tuesday's Biggest Analyst Calls: Apple, Tesla, Amazon, GM, Crocs, Viking, Alphabet, Ford & More
ShinyHunters Group Targets Over 100 Enterprises, Including Canva, Atlassian, and Epic Games
Dayra Therapeutics Secures Over $70M in Committed Funding
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Top Biotech Deals in March 2026
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
Diagnostics Lag Is Holding Back New Therapies, Says Study
Leqembi Starts to Deliver for Eisai and Biogen
Could Alzheimer's Be Predicted with a Finger-Prick Test?
The FDA Has Released Draft Guidance for NAMs Validation – Now What?
The New Gold Rush in Brain Science
STAT+: Pharmalittle: We’re Reading About Pharma Delaying Launches in Europe, Lilly and Biogen Deals, and More
Stelios Papadopoulos Brings the Long View on Biotech on The BioCentury Show
Biogen Price Target Raised to $200 From $190 at Morgan Stanley
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
The Next Wave of Biotech Growth — a Perspective
Roth/MKM Downgrades Apellis Stock Rating on Biogen Acquisition
InsideArbitrage Event Driven Monitor – April 1, 2026
This Biotech Firm Has Room to Run, Even as Its Drug Royalties Are Set to Shrink
Sanofi Appoints Specialty Care Head; Biogen Chair to Retire in June
Biogen to Acquire Apellis for $5.6 B, Shares Jump 136% on Deal
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Biogen's Stock Slumps as Biosimilars Hit MS Sales and Alzheimer Setbacks Loom
Biogen Stops Part of an MS Trial; Merck Reports More Enflonsia Data
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside From Biogen Merger
Prothena Announces Leadership Team Updates
ARS Pharma Secures FDA Label Expansion for Neffy Needle‑Free Epinephrine Spray
Biogen Filing Reveals Apellis Deal Details; Telix Raises $600M